Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Analyst Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GKOS Stock 12 Month Forecast
Average Price Target
$126.67
▲(34.68%Upside)
| Highest Price Target$165.00 | Average Price Target$126.67 | Lowest Price Target$92.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$94
Hold
-0.05%
Downside
Reiterated
07/31/25
The overall stock score reflects a mix of strong revenue growth and strategic advancements against the backdrop of ongoing profitability challenges and bearish technical indicators. Significant positive factors include robust sales growth and strategic pipeline developments, while the lack of profitability and negative cash flows remain key concerns.
Truist Financial
$130→$126
Buy
33.97%
Upside
Reiterated
07/31/25
Wells Fargo
$86→$92
Hold
-2.18%
Downside
Reiterated
07/31/25
Mizuho Securities
$150→$130
Buy
38.22%
Upside
Reiterated
07/31/25
UBS
$125→$134
Buy
42.48%
Upside
Reiterated
07/31/25
J.P. Morgan
$100→$110
Buy
16.96%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/31/25
Needham
$115
Buy
22.28%
Upside
Reiterated
07/31/25
Stifel Nicolaus
$115
Buy
22.28%
Upside
Reiterated
07/31/25
BTIG
$117→$118
Buy
25.47%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Glaukos (NYSE: GKOS)We maintain our Buy and adjust our PT to $118 (from $117) following 2Q25 results. GKOS reported 2Q25 rev. of $124.1M (29.7% Y/Y , 28.6% Y/Y xFx), relative to BTIG/Cons. ests. of $117.4M/$115.5M. Glaucoma rev. of $103.5M (36.4% Y/Y) was favorable to our est. of $97.2M as iDose contributed ~$31.0M coupled with a decline of 9.0% in the US legacy surgical glaucoma portfolio. Guidance for FY25 was raised modestly to $480M-$486M (from $475M - $485M previously) as the mix shifts toward iDose offset by slightly lower US Glaucoma sales and slight changes to OUS Glaucoma and Corneal Health. All told, we think the iDose results exceeded the Buyside expectations of $28M - $30M in the quarter which keeps investors supportive of the potential in iDose. Mgmt. commentary on growing MAC coverage and adoption should be viewed favorably by longs.
Citi
$140
Buy
48.86%
Upside
Reiterated
07/07/25
Jefferies
$160
Buy
70.12%
Upside
Assigned
06/04/25
Piper Sandler
$165
Buy
75.44%
Upside
Reiterated
05/23/25
Stephens
$140→$115
Buy
22.28%
Upside
Reiterated
05/02/25
Morgan Stanley
$120→$110
Sell
16.96%
Upside
Reiterated
02/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$94
Hold
-0.05%
Downside
Reiterated
07/31/25
The overall stock score reflects a mix of strong revenue growth and strategic advancements against the backdrop of ongoing profitability challenges and bearish technical indicators. Significant positive factors include robust sales growth and strategic pipeline developments, while the lack of profitability and negative cash flows remain key concerns.
Truist Financial
$130→$126
Buy
33.97%
Upside
Reiterated
07/31/25
Wells Fargo
$86→$92
Hold
-2.18%
Downside
Reiterated
07/31/25
Mizuho Securities
$150→$130
Buy
38.22%
Upside
Reiterated
07/31/25
UBS
$125→$134
Buy
42.48%
Upside
Reiterated
07/31/25
J.P. Morgan
$100→$110
Buy
16.96%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/31/25
Needham
$115
Buy
22.28%
Upside
Reiterated
07/31/25
Stifel Nicolaus
$115
Buy
22.28%
Upside
Reiterated
07/31/25
BTIG
$117→$118
Buy
25.47%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Glaukos (NYSE: GKOS)We maintain our Buy and adjust our PT to $118 (from $117) following 2Q25 results. GKOS reported 2Q25 rev. of $124.1M (29.7% Y/Y , 28.6% Y/Y xFx), relative to BTIG/Cons. ests. of $117.4M/$115.5M. Glaucoma rev. of $103.5M (36.4% Y/Y) was favorable to our est. of $97.2M as iDose contributed ~$31.0M coupled with a decline of 9.0% in the US legacy surgical glaucoma portfolio. Guidance for FY25 was raised modestly to $480M-$486M (from $475M - $485M previously) as the mix shifts toward iDose offset by slightly lower US Glaucoma sales and slight changes to OUS Glaucoma and Corneal Health. All told, we think the iDose results exceeded the Buyside expectations of $28M - $30M in the quarter which keeps investors supportive of the potential in iDose. Mgmt. commentary on growing MAC coverage and adoption should be viewed favorably by longs.
Citi
$140
Buy
48.86%
Upside
Reiterated
07/07/25
Jefferies
$160
Buy
70.12%
Upside
Assigned
06/04/25
Piper Sandler
$165
Buy
75.44%
Upside
Reiterated
05/23/25
Stephens
$140→$115
Buy
22.28%
Upside
Reiterated
05/02/25
Morgan Stanley
$120→$110
Sell
16.96%
Upside
Reiterated
02/26/25
Best Analysts Covering Glaukos
1 Month
xxx
Success Rate
9/10 ratings generated profit
Average Return
+6.31%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 90.00% of your transactions generating a profit, with an average return of +6.31% per trade.
3 Months
xxx
Success Rate
8/10 ratings generated profit
Average Return
+5.15%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +5.15% per trade.
1 Year
Success Rate
11/16 ratings generated profit
Average Return
+39.02%
reiterated a buy rating yesterday
Copying David Saxon's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +39.02% per trade.
2 Years
xxx
Success Rate
11/16 ratings generated profit
Average Return
+47.80%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +47.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GKOS Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
1
6
10
10
5
Buy
15
12
8
11
13
Hold
0
0
4
8
10
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
17
19
22
29
28
Each month's total comprises the sum of three months' worth of ratings.
GKOS Financial Forecast
GKOS Stock Forecast FAQ
What is GKOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Glaukos’s 12-month average price target is 126.67.
What is GKOS’s upside potential, based on the analysts’ average price target?
Glaukos has 34.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GKOS a Buy, Sell or Hold?
Glaukos has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
What is Glaukos’s price target?
The average price target for Glaukos is 126.67. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $165.00 ,the lowest forecast is $92.00. The average price target represents 34.68% Increase from the current price of $94.05.
The highest analyst price target is $165.00 ,the lowest forecast is $92.00. The average price target represents 34.68% Increase from the current price of $94.05.
What do analysts say about Glaukos?
Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of GKOS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.